Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation

Biomaterials

Volumn 63, Issue , 2015, Pages 168-176

  Li, Hui ^a   Guo, Lei ^b   Huang, Aixue ^a   Xu, Hua ^b   Liu, Xuemei ^a   Ding, Hongmei ^a   Dong, Jie ^a   Li, Jie ^a   Wang, Chaonan ^a   Su, Xueting ^a   Ge, Xingfeng ^a   Sun, Leqiao ^a   Bai, Chenjun ^a   Shen, Xuelian ^a   Fang, Tao ^a   Li, Zhanghua ^c   Zhou, Yong ^d   Zhan, Linsheng ^d   Li, Shaohua ^a   Xie, Jianwei ^b   Shao, Ningsheng ^a   more..

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c TONGREN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d Beijing Institute of Laboratory of Blood borne Virus   (China)

Author keywords

Aptamer; Heterogeneous nuclear ribonucleoprotein A2 B1; Nanoparticles; SELEX; Tumor cells

Indexed keywords

ANTIBODIES; CARBON; CELL CULTURE; CELLS; CYTOLOGY; DIAGNOSIS; MONOCLONAL ANTIBODIES; NANOPARTICLES;

APTAMERS; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN (HNRNP); INHIBITORY EFFECT; NANOPARTICLE CONJUGATE; NUCLEAR RIBONUCLEOPROTEIN; SELEX; TUMOR CELL LINES; TUMOR CELLS;

TUMORS;

APTAMER; CARBON NANOPARTICLE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN A2; HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN B1; MONOCLONAL ANTIBODY; QUANTUM DOT; UNCLASSIFIED DRUG; NANOCONJUGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MOUSE; MULTIPLE CANCER; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; NEOPLASMS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NANOCONJUGATES; NEOPLASMS; RATS;

EID: 84952653494     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.06.013     Document Type: Article

References (40)

1. Tuerk C., Gold L. Systeatic evolut ion of ligands by exponential enrichment :RNA 1igands to bacteriophage T4 DNA polymerase. Science 1990, 249(4968):505-510.
2. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346(6287):818-822.
3. Konopka K., Lee N.S., Rossi J., Duzqunes N. Rev-binding aptamer and CMV promoter a decoys to inhibit HIV replication. Gene 2000, 255(2):235-244.
4. Gal S.W., Amontov S., Urvil P.T., Vishnuvardhan D., Nishikawa F., Kumar P.K., et al. Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function. Eur. J. Biochem. 1998, 252(3):553-562.
5. Wang C.L., Zhang M., Yang G., Zhang D., Ding H., Wang H., et al. Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. Biotechnol 2003, 102:15-22.
6. Cao X., Li S., Chen L., Ding H., Xu H., Shao N., et al. Combining use of a panel of ssDNA aptamers in the detection of Staphylococcus aureus. Nucleic Acids Res. 2009, 37:4621-4628.
7. Li S., Xu H., Ding H., Huang Y., Cao X., Shao N., et al. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol. 2009, 218(3):327-336.
8. Tang Z., Shanggunan D., Wang K., Shi H., Sefah K., Tan W., et al. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 2007, 79:4900-4907.
9. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2. - Fluoropyrimidine RNA based aptamers to the 165- amino acid form of vascular endothelial growth factor(VEGF165). Inhibit ion of recept or binding and VEGF- induced vascular permeability through int eract ions requiring the exon 7- encoded domain. J. Biol. Chem. 1998, 273(32):20556-20567.
10. Andreola M.L., De Soultrait V.R., Fournier M., Parissi V., Desjobert C., Litvak S. HIV- 1 integrase and Rnase H activities as therapeutic targets. Expert Opin. Ther. Targets 2002, 6(4):433-446.
11. Li hui, Ding Hongmei, Shaohua Li, Jie Li, Aixue Huang, Ningsheng Shao, et al. Selection and identification of ssDNA aptamers specific to rat ROS1728 cells. Lett. Biotechnol. 2015, 26:81-84.
12. Golan-Gerstl R., Cohen M., Shilo A., Suh S.S., Bakacs A., Coppola L., et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 2011, 71(13):4464-4472.
13. Chen Z.Y., Cai L., Zhu J., Chen M., Chen J., Li Z.H., et al. Fyn requires HnRNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer. Carcinogenesis 2011, 32(10):1419-1426.
14. Moriconi F., Ramadori P., Schultze F.C., Blaschke M., Amanzada A., Khan S., et al. Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development. Histochem Cell Biol. 2013, 139(3):473-485.
15. M1 Ferracin, Bassi C., Pedriali M., Pagotto S., D'Abundo L., Zagatti B., et al. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol. Cancer 2013, 12(1):130.
16. Eddy J., Maizels N. Conserved elements with potential to form poly-morphic G-quadruplex structures in the first intron of human genes. Nucleic Acids Res. 2008, 36(4):1321-1333.
17. Barrandon C., Bonnet F., Nguyen V.T., Labas V., Bensaude O. The transcription-dependent dissociation of P-TEFb-HEXIM1-7SK RNA relies upon formation of hnRNP-7SK RNA complexes. Mol. Cell Biol. 2007, 27(20):6996-7006.
18. Martinez-Contreras R., Cloutier P., Shkreta L., Fisette J.F., Revil T., Chabot B. hnRNP proteins and splicing control. Adv. Exp. Med. Biol. 2007, 623:123-147.
19. Rooke N., Markovtsov V., Cagavi E., Black D.L. Roles for SR proteins and hnRNP A1 in the regulation of c-src exon N1. Mol. Cell Biol. 2003, 23(6):1874-1884.
20. Iijima M., Suzuki M., Tanabe A., Yamada M. Two motifs essential for nuclear import of the hnRNP A1 nucleocytoplasmic shuttling sequence M9 core. FEBS Lett. 2006, 580(5):1365-1370.
21. Allemand E., Guil S., Myers M., Moscat J., Cáceres J.F., Krainer A.R. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(10):3605-3610.
22. Cui H., Wu F., Sun Y., Fan G., Wang Q. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma. BMC Cancer 2010, 10:356.
23. Jing G.J., Xu D.H., Shi S.L., Li Q.F., Wang S.Y., Wu F.Y., et al. Aberrant expression of nuclear matrix proteins during HMBA-induced differentiation of gastric cancer cells. World J. Gastroenterol. 2010, 16(17):2176-2182.
24. Torosyan Y., Dobi A., Glasman M., Mezhevaya K., Naga S., Huang W. Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells. Oncogene 2010, 29(17):2457-2466.
25. Tockman M.S., Gupta P.K., Myers J.D., Frost J.K., Baylin S.B., Gold E.B., et al. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen onpreserved sputum cells:a new approach to early lung cancer detection. J. Clin. Oncol. 1988, 6(11):1685-1693.
26. Sheng W., Chen T., Tan W., Fan Z.H. Multivalent DNA nanospheres for enhanced capture of cancer cells in microfluidic devices. ACS Nano 2013, 7(8):7067-7076.
27. Shen Q., Xu L., Zhao L., Wu D., Fan Y., Zhou Y., et al. Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates. Adv. Mater. 2013, 25(16):2368-2373.
28. Park J.H., von Maltzahn G., Xu M.J., Fogal V., Kotamraju V.R., Ruoslahti E., et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:981-986.
29. Liu Q., Jin C., Wang Y., Fang X., Zhang X., Chen Z., Tan W. Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy. NPG Asia Mater. 2014, 6:e95.
30. Ara M.N., Matsuda T., Hyodo M., Sakurai Y., Hatakeyama H., Ohga N., et al. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. Biomaterials 2014, 35:7110-7120.
31. Xu W., Siddiqui I.A., Nihal M., Pilla S., Rosenthal K., Mukhtar H., et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 2013, 34:5244-5253.
32. Li S., Chen N., Zhang Z., Wang Y. Endonuclease-responsive aptamer-functionalized hydrogel coating for sequential catch and release of cancer cells. Biomaterials 2013, 34:460-469.
33. Kim J.K., Choi K.-J., Lee M., Jo M-h, Kim S. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 2012, 33:207-217.
34. Cai L., Chen Z.-Z., Chen M.-Y., Tang H.-W., Pang D.-W. MUC-1 aptamer-conjugated dye-doped silica nanoparticles for MCF-7 cells detection. Biomaterials 2013, 34:371-381.
35. Wang F.-B., Rong Y., Fang M., Yuan J.-P., Peng C.-W., Liu S.-P., et al. Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles. Biomaterials 2013, 34:3816-3827.
36. Kim M.-G., Park J.Y., Miao W., Lee J., Oh Y.-K. Polyaptamer DNA nanothread-anchored, reduced graphene oxide nanosheets for targeted delivery. Biomaterials 2015, 48:129-136.
37. Baker S.N., Baker G.A. Luminescent carbon nanodots: emergent nanolights. Angew. Chem. Int. Ed. Enql. 2010, 49(38):6726-6744.
38. Ray S.C., Saha A., Jana N.R., Sarkar R. Fluorescent carbon nanoparticles: synthesis,characterization, and bioimaging application. J. Phys. Chem. C 2009, 113:18546-18551.
39. Jana N.R. Design and development of quantum dots and other nanoparticles based cellular imaging probe. Phys. Chem. Chem. Phys. 2011, 13(2):385-396.
40. Zhang Z., Guo L., Guo A., Xu H., Tang J., Guo X., et al. In vitro lectin-mediated selection and characterization of rHuEPO-α-binding ssDNA aptamers. Bioorg. Med. Chem. 2010, 18(22):8016-8025.